From standardization of imaging techniques, to more reproducible and cost-effective organoid culture media

Organoids have the potential to revolutionize current drug discovery approaches, enhance the physiological relevance of in vitro disease models, and deliver on the promise of precision medicine. But, as with any new technology, there are a number of hurdles to overcome as pharma and biotech look to scale-up their organoid models and incorporate them routinely into their assay workflows.

We recently partnered with CytoSMART and organoid pioneers from both academia and industry to facilitate an open and collaborative webinar discussion about the key hurdles facing pharma and biotech companies as they approach this pivotal stage of their organoid R&D programs. In particular, we discussed the opportunities organoids offer and the challenges faced when scaling up applications, including standardization of imaging techniques, as well as the need for more reproducible, cost-effective chemically-defined organoid culture media to support the seamless transition from bench to clinical-based applications

In this free webinar, we heard presentations from the following organoid pioneers:

• Dr. René M. Overmeer, Head of Assay Development & Automation at Hubrecht Organoid Technology. Presentation: “Reliable High throughput screening using organoids”
• Dr. Dennis Plenker, Research Investigator Laboratory of Dr. David Tuveson and Technical Manager Organoid Facility at Cold Spring Harbor Laboratory. Presentation: “Human organoid growth conditions – from media to organoid cultures”
• Dr. Ruchi Sharma, CEO & Founder Stemnovate. Presentation: “Tissue engineering, organoids or organ systems: challenges and opportunities”

Join hosts, Dr. Inge Thijssen van Loosdregt, Field Application Engineer, CytoSMART and Rob Nixon, Head of Commercial, Qkine. Presentation, and watch our on-demand webinar featuring a thought provoking Q&A session with the speakers.